Adjuvant T-DM1 Provides Sustained Survival Benefit in HER2+

Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.

Related Keywords

San Antonio , Texas , United States , Germany , Neu Isenburg , Hessen , German , , Centre For Haematology , German Breast Group , Goethe University , Antonio Breast Cancer , Sibylle Loibl , Oncology Bethanien , San Antonio Breast Cancer Symposium , Hr Positive , Er2 Negative Early Stage Breast Cancer , Adjuvantt Dm1 , Btrastuzumab , Katherine , Ct01772472 ,